Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Scientific Reports
|
March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma
Christopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Sarcoma
|
August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Future Oncology (London, England)
|
February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M Cote, Sant P Chawla, George Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics
Christopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Science Advances
|
March 31, 2023
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity
Rajendran Sanalkumar, Rui Dong, Lukuo Lee, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated Chondrosarcoma
Yin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Scientific Reports
|
March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma
Christopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Sarcoma
|
August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Future Oncology (London, England)
|
February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma
Gregory M Cote, Sant P Chawla, George Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics
Christopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Science Advances
|
March 31, 2023
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity
Rajendran Sanalkumar, Rui Dong, Lukuo Lee, et al.
Nature Communications
|
March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Mrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated Chondrosarcoma
Yin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Page
of 10